UNSPSC 51183102: Alrestatin sodium

This classification denotes an aldose reductase inhibitor with the molecular structure C14H8NO4.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 018XNU6812 chemically known as 1h-benz(de)isoquinoline-2(3h)acetic acid, 1,3-dioxo-, sodium salt, but more commonly known as alrestatin sodium, which bears US NIH Compound Identifier 40158. European Medicines Agency schedules Alrestatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00380MIG.

Most nations, for tariff and trade purposes, schedule alrestatin sodium under HS 29251995 and SITC 51482. As of Q4 2014, ALRESTATIN SODIUM remains US FDA's Preferred Term for this commodity. Alrestatin sodium bears US NLM identifiers UMLS ID C2346724 and NCI Concept Code C72691. SMILES: C1CC2CCCC3C2C(C1)C(=O)N(C3=O)CC(=O)[O-].[NA+].

UNSPSC 51183102 Alrestatin sodium is a Commodity code covering pharmaceutical active ingredients and finished drugs supplied through state and local cooperative purchasing vehicles. The recent MMCAP solicitation shows that state and local governments actually procure generic pharmaceuticals and over-the-counter products through multistate cooperative agreements, where manufacturers supply products identified by National Drug Code, SKU, and packaging configuration to authorized wholesalers serving multiple state and local facilities. The scope includes compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements, with products distributed through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—that maintain chargeback systems and EDI capability. Vendors are required to maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and all products must have expiration dates of at least one year from manufacture with a minimum six-month shelf life.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, seeking multiple contract awards for generic pharmaceuticals and OTC products to serve participating state and local government facilities, including Oregon. The contract term is two years for new responders with optional extensions, with awarded vendors effective July 1, 2026. Evaluation is weighted toward price competitiveness (75 percent), with secondary criteria including fixed pricing structure (10 percent), compliance with administrative requirements and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs; specific award values or budget ranges are not disclosed.